DE60009480D1 - Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren - Google Patents

Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren

Info

Publication number
DE60009480D1
DE60009480D1 DE60009480T DE60009480T DE60009480D1 DE 60009480 D1 DE60009480 D1 DE 60009480D1 DE 60009480 T DE60009480 T DE 60009480T DE 60009480 T DE60009480 T DE 60009480T DE 60009480 D1 DE60009480 D1 DE 60009480D1
Authority
DE
Germany
Prior art keywords
linkage
heteroaryldiyl
compounds
aryldiyl
heterocycloalkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009480T
Other languages
English (en)
Other versions
DE60009480T2 (de
Inventor
Paul Robert Eastwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910396.2A external-priority patent/GB9910396D0/en
Priority claimed from GBGB9910417.6A external-priority patent/GB9910417D0/en
Priority claimed from GBGB9910405.1A external-priority patent/GB9910405D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of DE60009480D1 publication Critical patent/DE60009480D1/de
Publication of DE60009480T2 publication Critical patent/DE60009480T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
DE60009480T 1999-05-05 2000-05-05 Harnstoffe als modulatoren der zelladhäsion Expired - Lifetime DE60009480T2 (de)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB9910417 1999-05-05
GBGB9910396.2A GB9910396D0 (en) 1999-05-05 1999-05-05 Chemical compounds
GB9910405 1999-05-05
GBGB9910417.6A GB9910417D0 (en) 1999-05-05 1999-05-05 Chemical compounds
GBGB9910405.1A GB9910405D0 (en) 1999-05-05 1999-05-05 Chemical compounds
GB9910396 1999-05-05
US15285599P 1999-09-08 1999-09-08
US15286199P 1999-09-08 1999-09-08
US15286099P 1999-09-08 1999-09-08
US152855P 1999-09-08
US152860P 1999-09-08
US152861P 1999-09-08
PCT/GB2000/001734 WO2000068223A1 (en) 1999-05-05 2000-05-05 Ureas and their use as cell adhesion modulators

Publications (2)

Publication Number Publication Date
DE60009480D1 true DE60009480D1 (de) 2004-05-06
DE60009480T2 DE60009480T2 (de) 2005-09-01

Family

ID=27547334

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009480T Expired - Lifetime DE60009480T2 (de) 1999-05-05 2000-05-05 Harnstoffe als modulatoren der zelladhäsion

Country Status (8)

Country Link
US (1) US6620832B2 (de)
EP (1) EP1177186B1 (de)
AT (1) ATE263162T1 (de)
AU (1) AU4591800A (de)
CA (1) CA2370805C (de)
DE (1) DE60009480T2 (de)
ES (1) ES2218156T3 (de)
WO (1) WO2000068223A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE524441T1 (de) 2000-12-28 2011-09-15 Daiichi Seiyaku Co Vla-4-inhibitoren
ES2393900T3 (es) * 2001-12-03 2012-12-28 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
US7767670B2 (en) * 2003-11-13 2010-08-03 Ambit Biosciences Corporation Substituted 3-carboxamido isoxazoles as kinase modulators
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (de) 2005-09-14 2008-05-28 Amgen, Inc Konformationseingeschränkte 3- (4-hydroxy-phenyl) substitutierte propansäuren zur behandlung von stoffwechselstörungen
EP2061760A1 (de) * 2006-09-07 2009-05-27 Amgen, Inc Benzokondensierte verbindungen zur verwendung bei der behandlung von stoffwechselerkrankungen
US7714008B2 (en) * 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
WO2008130514A1 (en) * 2007-04-16 2008-10-30 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
WO2015145371A1 (en) * 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212320A (en) * 1990-05-21 1993-05-18 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives and their use for testosterone 5-alpha-reductase-mediated diseases
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP3555876B2 (ja) * 1997-08-22 2004-08-18 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−アロイルフェニルアラニン誘導体
WO1999020272A1 (en) * 1997-10-21 1999-04-29 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
SK12742000A3 (sk) * 1998-02-25 2001-05-10 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
TR200100588T2 (tr) * 1998-08-26 2001-08-21 Pharma Limited Aventis Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.
AP2000001924A0 (en) * 1998-12-23 2000-09-30 Aventis Pharma Ltd Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines.
SE514227C2 (sv) 1999-01-20 2001-01-22 Tore Kaellander Anordning inrättad att kyla ett maskinaggregat som är inrättat att vara associerat med en motor

Also Published As

Publication number Publication date
EP1177186A1 (de) 2002-02-06
ATE263162T1 (de) 2004-04-15
EP1177186B1 (de) 2004-03-31
WO2000068223A8 (en) 2001-03-01
ES2218156T3 (es) 2004-11-16
CA2370805C (en) 2012-07-03
DE60009480T2 (de) 2005-09-01
WO2000068223A1 (en) 2000-11-16
CA2370805A1 (en) 2000-11-16
US6620832B2 (en) 2003-09-16
AU4591800A (en) 2000-11-21
US20020082255A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
ATE263162T1 (de) Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren
BG106083A (en) Substituted bicyclic heteroaryl compounds as integrin antagonists
NO20020725D0 (no) Celleadhesjonsinhibitorer
TW368500B (en) 1-Benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
MXPA01001995A (es) Aza-biciclos que modulan la inhibicion de adhesion celular.
PE106499A1 (es) Antagonistas del receptor ccr-3
ATE390404T1 (de) Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
TR199901674T2 (de)
ATE466861T1 (de) Aminderivate
AR015964A1 (es) Compuestos de isoquinolina, su uso, procedimiento para tratar una afeccion, procedimiento de preparacion del compuesto, composicion farmaceutica que locontiene y compuesto util en dicho procedimiento
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
DE59707524D1 (de) 1,3-bis-(n-lactamyl)propane und deren pharmazeutische und kosmetische verwendung
IL42879A (en) N-(5(4)-imidazolyl-(alkyl,alkylthioalkyl or alkylaminoalkyl)) guanidine derivatives their preparation and pharmaceutical compositions containing them
ATE281433T1 (de) Substituierte pyrrolidine als inhibitoren der zelladhäsion
NO970513L (no) Urokinase-reseptorligander
CO5140091A1 (es) Derivados de piperidina y piperazina, su preparacion, su uso como productos farmaceuticos y composiciones farmaceuticas que los contienen
AP2000001924A0 (en) Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines.
HUP0103309A2 (hu) N-(terc-Butil)-hidroxil-amin új sói és előállításuk
CO5160333A1 (es) Derivados de tetrazina pesticidamente activos y composicion que los contine
MA33107B1 (fr) Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
DE69617001D1 (de) (2-morpholinylmethyl)benzamid-derivate
YU71501A (sh) Supstituisana biciklična heteroaril jedinjenja kao antagonisti integrina
EA200001077A2 (ru) Новые соединения аминопирролина, способ их получения и содержащие их фармацевтические композиции
WO2001042192A3 (en) Vla-4 integrin antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition